Zoledronate induces autophagic cell death in human umbilical vein endothelial cells via Beclin-1 dependent pathway activation

Lu,Yong; Wang,Zhiyong; Han,Wei; Li,Hao

doi:10.3892/mmr.2016.5834

Zoledronate induces autophagic cell death in human umbilical vein endothelial cells via Beclin-1 dependent pathway activation

Authors:
- Yong Lu
- Zhiyong Wang
- Wei Han
- Hao Li
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P.R. China
Published online on: October 12, 2016 https://doi.org/10.3892/mmr.2016.5834
Pages: 4747-4754
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Zoledronate has been reported to exhibit pro‑apoptotic and anti-angiogenic effects in endothelial cells, which partially contributes to bisphosphonate‑associated osteonecrosis of the jaw (BP‑ONJ). Zoledronate can also induce autophagic cell death. The present study hypothesized that Zoledronate may activate autophagy to exert pro‑apoptotic effects in endothelial cells and aimed to investigate the effect of Zoledronate on human umbilical vein endothelial cells (HUVECs) and explore the underlying mechanisms. The current study demonstrated that Zoledronate induced autophagy in HUVECs in a dose‑dependent manner, as demonstrated by increased levels of microtubule‑associated proteins 1A/1B light chain 3B‑II (LC3B‑II) and Beclin‑1, and decreased levels of sequestome 1 (SQSTM1). In addition, treatment with chloroquine further increased LC3B‑II and increased SQSTM1 levels, indicating that Zoledronate induces autophagy by increasing autophagic activity. Flow cytometry and Hoechst 33258 staining revealed that inhibition of autophagy with 3-methyladenine markedly attenuated Zoledronate‑induced apoptosis. Furthermore, genetic knockdown of Beclin‑1 significantly inhibited autophagy and apoptosis induced by Zoledronate. The present study therefore demonstrated that Zoledronate may promote Beclin‑1‑mediated autophagy to induce endothelial cell apoptosis, and suggests that blocking autophagy may represent a novel approach for the prevention of BP‑ONJ in patients receiving Zoledronate.

View Figures

View References

1	Bassett CA, Donath A, Macagno F, Preisig R, Fleisch H and Francis MD: Diphosphonates in the treatment of myositis ossificans. Lancet. 2:8451969. View Article : Google Scholar : PubMed/NCBI
2	Selander KS, Mönkkönen J, Karhukorpi EK, Härkönen P, Hannuniemi R and Väänänen HK: Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol. 50:1127–1138. 1996.PubMed/NCBI
3	Brown DL and Robbins R: Developments in the therapeutic applications of bisphosphonates. J Clin Pharmacol. 39:651–660. 1999. View Article : Google Scholar : PubMed/NCBI
4	Tsai SH, Huang PH, Chang WC, Tsai HY, Lin CP, Leu HB, Wu TC, Chen JW and Lin SJ: Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. PloS One. 7:e410652012. View Article : Google Scholar : PubMed/NCBI
5	Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE and Holen I: Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther. 8:2821–2832. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, Yatani H and Yoneda T: Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab. 28:165–175. 2010. View Article : Google Scholar : PubMed/NCBI
7	Yamashita J, Koi K, Yang DY and McCauley LK: Effect of zoledronate on oral wound healing in rats. Clin Cancer Res. 17:1405–1414. 2011. View Article : Google Scholar : PubMed/NCBI
8	Diel IJ, Bergner R and Grötz KA: Adverse effects of bisphosphonates: Current issues. J Support Oncol. 5:475–482. 2007.PubMed/NCBI
9	Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE and Mehrotra B: American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67 (5 Suppl). 2–12. 2009. View Article : Google Scholar
10	Russell RG: Bisphosphonates: From bench to bedside. Ann NY Acad Sci. 1068:367–401. 2006. View Article : Google Scholar : PubMed/NCBI
11	Allen MR and Burr DB: Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 66:987–994. 2008. View Article : Google Scholar : PubMed/NCBI
12	Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J and Wagner W: Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 54:1066–1072. 2008. View Article : Google Scholar : PubMed/NCBI
13	Reid IR, Bolland MJ and Grey AB: Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 41:318–320. 2007. View Article : Google Scholar : PubMed/NCBI
14	Walter C, Pabst A, Ziebart T, Klein M and Al-Nawas B: Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis. 17:194–199. 2011. View Article : Google Scholar : PubMed/NCBI
15	Giraudo E, Inoue M and Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 114:623–633. 2004. View Article : Google Scholar : PubMed/NCBI
16	Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, et al: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 9:2893–2897. 2003.PubMed/NCBI
17	Cetinkaya BO, Keles GC, Ayas B and Gurgor P: Effects of risedronate on alveolar bone loss and angiogenesis: A stereologic study in rats. J Periodontol. 79:1950–1961. 2008. View Article : Google Scholar : PubMed/NCBI
18	Khandelwal VK, Mitrofan LM, Hyttinen JM, Chaudhari KR, Buccione R, Kaarniranta K, Ravingerová T and Mönkkönen J: Oxidative stress plays an important role in zoledronic acid-induced autophagy. Physiol Res. 63:(Suppl 4). S601–S612. 2014.PubMed/NCBI
19	Mizushima N and Levine B: Autophagy in mammalian development and differentiation. Nat Cell Biol. 12:823–830. 2010. View Article : Google Scholar : PubMed/NCBI
20	Rubinsztein DC, Mariño G and Kroemer G: Autophagy and aging. Cell. 146:682–695. 2011. View Article : Google Scholar : PubMed/NCBI
21	Wang IT, Chou SC and Lin YC: Zoledronic acid induces apoptosis and autophagy in cervical cancer cells. Tumour Biol. 35:11913–11920. 2014. View Article : Google Scholar : PubMed/NCBI
22	Ge XY, Yang LQ, Jiang Y, Yang WW, Fu J and Li SL: Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83. PloS One. 9:e1012072014. View Article : Google Scholar : PubMed/NCBI
23	Lin JF, Lin YC, Lin YH, Tsai TF, Chou KY, Chen HE and Hwang TI: Zoledronic acid induces autophagic cell death in human prostate cancer cells. J Urol. 185:1490–1496. 2011. View Article : Google Scholar : PubMed/NCBI
24	Lv XH, Zhao DH, Cai SZ, Luo SY, You T, Xu BL and Chen K: Autophagy plays a protective role in cell death of osteoblasts exposure to lead chloride. Toxicol Lett. 239:131–140. 2015. View Article : Google Scholar : PubMed/NCBI
25	Bezzi M, Hasmim M, Bieler G, Dormond O and Rüegg C: Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem. 278:43603–43614. 2003. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, et al: Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 4:151–175. 2008. View Article : Google Scholar : PubMed/NCBI
28	Ichimura Y and Komatsu M: Selective degradation of p62 by autophagy. Semin Immunopathol. 32:431–436. 2010. View Article : Google Scholar : PubMed/NCBI
29	Pattingre S, Espert L, Biard-Piechaczyk M and Codogno P: Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie. 90:313–323. 2008. View Article : Google Scholar : PubMed/NCBI
30	Esteban-Martinez L and Boya P: Autophagic flux determination in vivo and ex vivo. Methods. 75:79–86. 2015. View Article : Google Scholar : PubMed/NCBI
31	Leist M and Jäättelä M: Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2:589–598. 2001. View Article : Google Scholar : PubMed/NCBI
32	Moscat J and Diaz-Meco MT: p62 at the crossroads of autophagy, apoptosis, and cancer. Cell. 137:1001–1004. 2009. View Article : Google Scholar : PubMed/NCBI
33	Shvets E, Fass E and Elazar Z: Utilizing flow cytometry to monitor autophagy in living mammalian cells. Autophagy. 4:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
34	Wasko BM, Dudakovic A and Hohl RJ: Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J Pharmacol Exp Ther. 337:540–546. 2011. View Article : Google Scholar : PubMed/NCBI
35	Iwai-Kanai E, Yuan H, Huang C, Sayen MR, Perry-Garza CN, Kim L and Gottlieb RA: A method to measure cardiac autophagic flux in vivo. Autophagy. 4:322–329. 2008. View Article : Google Scholar : PubMed/NCBI
36	Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, et al: Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 81:1047–1053. 2006. View Article : Google Scholar : PubMed/NCBI
37	Wang EP, Kaban LB, Strewler GJ, Raje N and Troulis MJ: Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 65:1328–1331. 2007. View Article : Google Scholar : PubMed/NCBI
38	Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M and Clézardin P: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62:6538–6544. 2002.PubMed/NCBI
39	Zhuang W, Qin Z and Liang Z: The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai). 41:341–351. 2009. View Article : Google Scholar : PubMed/NCBI
40	Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999. View Article : Google Scholar : PubMed/NCBI